These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22008135)

  • 1. [Significance of 3-methoxytyramine urine measurement in the diagnosis of pheochromocytomas and paragangliomas: about 28 patients].
    Le Jacques A; Abalain JH; Le Saos F; Carré JL
    Ann Biol Clin (Paris); 2011; 69(5):555-9. PubMed ID: 22008135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas.
    Patin F; Crinière L; Francia T; Kassem S; Pierre P; Bruno C; Vayne C; Vourc'h P; Benz-de Bretagne I; Andres CR; Blasco H
    Clin Biochem; 2016 Oct; 49(15):1205-1208. PubMed ID: 27208558
    [No Abstract]   [Full Text] [Related]  

  • 3. Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?
    Peitzsch M; Kaden D; Pamporaki C; Langton K; Constantinescu G; Conrad C; Fliedner S; Sinnott RO; Prejbisz A; Därr R; Lenders JWM; Bursztyn M; Eisenhofer G
    Eur J Endocrinol; 2020 May; 182(5):499-509. PubMed ID: 32187575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deconjugated urinary metanephrine, normetanephrine and 3-methoxytyramine in laboratory diagnosis of pheochromocytoma and paraganglioma.
    Bílek R; Zelinka T; Vlček P; Dušková J; Michalský D; Novák K; Bešťák J; Widimský J
    Physiol Res; 2015; 64(Suppl 2):S313-22. PubMed ID: 26680494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
    Eisenhofer G; Brown S; Peitzsch M; Pelzel D; Lattke P; Glöckner S; Stell A; Prejbisz A; Fassnacht M; Beuschlein F; Januszewicz A; Siegert G; Reichmann H
    Ann Clin Biochem; 2014 Jan; 51(Pt 1):38-46. PubMed ID: 23873873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of plasma free metanephrines in diagnosis of pheochromocytomas and paragangliomas in the population of Asturias.
    Martínez-Morillo E; Valdés Gallego N; Eguia Ángeles E; Fernández Fernández JC; Prieto García B; Álvarez FV
    Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):312-319. PubMed ID: 30391255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma.
    Christensen TT; Frystyk J; Poulsen PL
    Scand J Clin Lab Invest; 2011 Dec; 71(8):695-700. PubMed ID: 22023043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
    Rao D; Peitzsch M; Prejbisz A; Hanus K; Fassnacht M; Beuschlein F; Brugger C; Fliedner S; Langton K; Pamporaki C; Gudziol V; Stell A; Januszewicz A; Timmers HJLM; Lenders JWM; Eisenhofer G
    Eur J Endocrinol; 2017 Aug; 177(2):103-113. PubMed ID: 28476870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
    Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
    Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory evaluation of pheochromocytoma and paraganglioma.
    Eisenhofer G; Peitzsch M
    Clin Chem; 2014 Dec; 60(12):1486-99. PubMed ID: 25332315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological diagnosis of pheochromocytoma: is there an interest in urinary metanephrines measurement over 3 consecutive days?].
    Bettacchioli É; Leven C; Thuillier P; Plée-Gautier E; Lapègue M; Carré JL; Padelli M
    Ann Biol Clin (Paris); 2018 Oct; 76(5):537-544. PubMed ID: 30174318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Urinary Catecholamine Excretion and Urine Volume.
    Haap M; Blaschka F; Lehmann R; Hoyer A; Müssig K
    Horm Metab Res; 2019 Aug; 51(8):531-538. PubMed ID: 31174227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors.
    Procopiou M; Finney H; Akker SA; Chew SL; Drake WM; Burrin J; Grossman AB
    Eur J Endocrinol; 2009 Jul; 161(1):131-40. PubMed ID: 19383804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.
    Eisenhofer G; Goldstein DS; Sullivan P; Csako G; Brouwers FM; Lai EW; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2068-75. PubMed ID: 15644397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated
    Eisenhofer G; Prejbisz A; Peitzsch M; Pamporaki C; Masjkur J; Rogowski-Lehmann N; Langton K; Tsourdi E; Pęczkowska M; Fliedner S; Deutschbein T; Megerle F; Timmers HJLM; Sinnott R; Beuschlein F; Fassnacht M; Januszewicz A; Lenders JWM
    Clin Chem; 2018 Nov; 64(11):1646-1656. PubMed ID: 30097498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors affecting spot urine fractionated metanephrines in patients suspected pheochromocytoma/paraganglioma.
    Bokuda K; Yatabe M; Seki Y; Ichihara A
    Hypertens Res; 2020 Jun; 43(6):543-549. PubMed ID: 32020083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors.
    de Jong WH; Eisenhofer G; Post WJ; Muskiet FA; de Vries EG; Kema IP
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2841-9. PubMed ID: 19567530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population.
    Brain KL; Kay J; Shine B
    Clin Chem; 2006 Nov; 52(11):2060-4. PubMed ID: 16990424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Random 'spot' urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas.
    Sbardella E; Maunsell Z; May CJH; Tadman M; James T; Jafar-Mohammadi B; Isidori AM; Grossman AB; Shine B
    Eur J Endocrinol; 2020 Aug; 183(2):129-139. PubMed ID: 32413848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary normetanephrine and metanephrine measured by radioimmunoassay for the diagnosis of pheochromocytoma: utility of 24-hour and random 1-hour urine determinations.
    Oishi S; Sasaki M; Ohno M; Sato T
    J Clin Endocrinol Metab; 1988 Sep; 67(3):614-8. PubMed ID: 3410942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.